Endoplasmic reticulum stress inhibition attenuates hypertensive chronic kidney disease through reduction in proteinuria.
Endoplasmic reticulum (ER) stress is implicated in chronic kidney disease (CKD) development in patients and in animal models. Here we show that ER stress inhibition through 4-phenylbutyric acid (4-PBA) administration decreases blood pressure, albuminuria, and tubular casts in an angiotensin II/deoxycorticosterone acetate/salt murine model of CKD. Lower albuminuria in 4-PBA-treated mice was associated with higher levels of cubilin protein in renal tissue membrane fractions. 4-PBA decreased renal interstitial fibrosis, renal CD3+T-cell and macrophage infiltration, mRNA expression of TGFβ1, Wnt signaling molecules, and ER stress-induced pro-inflammatory genes. CHOP deficient mice that underwent this model of CKD developed hypertension comparable to wild type mice, but had less albuminuria and tubular casts. CHOP deficiency resulted in higher nephrin levels and decreased glomerulosclerosis compared to wild type mice; this effect was accompanied by lower macrophage infiltration and fibrosis. Our findings portray ER stress inhibition as a means to alleviate hypertensive CKD by preserving glomerular barrier integrity and tubular function. These results demonstrate ER stress modulation as a novel target for preserving renal function in hypertensive CKD.
Department of Medicine, Division of Nephrology, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Zahraa
Z
Mohammed-Ali
Department of Medicine, Division of Nephrology, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Chao
C
Lu
Department of Medicine, Division of Nephrology, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Mandeep K
MK
Marway
Department of Medicine, Division of Nephrology, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Rachel E
RE
Carlisle
Department of Medicine, Division of Respirology, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Kjetil
K
Ask
Department of Pathology and Molecular Medicine, McMaster University and St. Joseph's Healthcare Hamilton, Ontario, Canada.
Dusan
D
Lukic
Department of Medicine, Division of Nephrology, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Joan C
JC
Krepinsky
Department of Medicine, Division of Nephrology, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
Jeffrey G
JG
Dickhout
D000804:Angiotensin II / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000235:genetics; D001706:Biopsy; D001794:Blood Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D059865:Endoplasmic Reticulum Stress / Q000187:drug effects*; D005355:Fibrosis; D020869:Gene Expression Profiling; D006801:Humans; D006973:Hypertension / Q000209:etiology* / Q000378:metabolism*; D007249:Inflammation / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009400:Nephrosclerosis / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D010654:Phenylbutyrates / Q000494:pharmacology; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology*; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D051742:Transcription Factor CHOP / Q000172:deficiency; D059467:Transcriptome; D016482:Urinalysis
D010654:Phenylbutyrates; D000804:Angiotensin II; D051742:Transcription Factor CHOP; C075773:4-phenylbutyric acid